Efficacy and Safety of Intraperitoneal Bupivacaine Alone or with Dexmedetomidine on Postoperative Analgesia after Laparoscopic Cholecystectomy

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR201708002497386

Enrollment

120

Registered

2017-08-03

Start date

2017-06-03

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Surgery Postoperative pain

Interventions

patients will receive intraperitoneal bupivacaine (sunny marcaine) 50 ml 0.25% (125 mg) + intraperit

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: ASA physical status I and II of both sex and Age group18-60 years old) undergoing elective laparoscopic cholecystectomy under general anesthesia.

Exclusion criteria

Exclusion criteria: Patients with hypersensitivity or intolerance to the study drugs, severe renal dysfunction, severe hepatic dysfunction where metabolism of the drug may be greatly altered, severe cardiac disease with low cardiac output or conduction abnormalities as heart block, history of psychiatric illness, leaving intra abdominal drain at end of surgery and intraoperative change from laparoscopic to open surgery will be excluded from the study.

Design outcomes

Primary

Measure	Time frame
¿Postoperative visual analogue score will be recorded immediately postoperative and at 1, 6, 12 and 24 hours;¿First time to request analgesia in minutes	—

Secondary

Measure	Time frame
¿ Postoperative 24 hours analgesic requirement (pethidine) in mg.	—

Countries

Egypt

Contacts

Public ContactSamaa Rashwan

assitant professor

doaa_rashwan@hotmail.com01011270763

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026